North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-01-02-03 Thiazolidinediones
Links
MHRA Drug Safety Update (Jun 2019): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued- MHRA Drug Safety Update (October 2024) : GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
- MHRA Drug Safety Updates: SGLT2 inhibitors
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
NENC Guideline For Use Of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) in Adults- NICE NG 28: Type 2 diabetes in adults: management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA248: MR exenatide
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA315: Canagliflozin for type 2 diabetes
- NICE TA336: Empagliflozin for type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
- NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA775: Dapagliflozin for treating chronic kidney disease
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA924: Tirzepatide for treating type 2 diabetes
- NICE TA942: Empagliflozin for treating chronic kidney disease
- North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines
- NTAG Endocrine System Recommendations
- NTAG Treatment Appraisal: Oral semaglutide for the treatment of type 2 diabetes mellitus.
- PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity